Influenza and respiratory syncytial virus. Update on infection, management, and prevention (Q33889558)

29 July 2017

1 reference

title

Influenza and respiratory syncytial virus. Update on infection, management, and prevention (English)

1 reference

29 July 2017

Malhotra A

1

1 reference

29 July 2017

Krilov LR

series ordinal

2

1 reference

29 July 2017

publication date

1 April 2000

1 reference

Pediatric Clinics of North America

29 July 2017

published in

1 reference

29 July 2017

volume

47

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

353-72, vi-vii

1 reference

CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Analysis of the local and systemic immune responses induced in BALB/c mice by experimental respiratory syncytial virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Improvement of inactivated influenza virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Preclinical development of low toxicity drugs: focus on zanamivir, an anti-influenza drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Influenza virus RNA in the lung and lymphoid tissue of immunologically intact and CD4-depleted mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Emerging infections: pandemic influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Influenza virus infections in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Influenza vaccine in unprimed children: improved immunogenicity with few reactions following one high dose of split-product vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Prospects for a respiratory syncytial virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Modes of transmission of respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Nosocomial Respiratory Syncytial Virus Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Neonatal respiratory syncytial virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Respiratory syncytial viral infection in children with compromised immune function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Albuterol responsiveness in infants with respiratory failure caused by respiratory syncytial virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Surveillance for pandemic influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Molecular basis of resistance of influenza A viruses to amantadine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Antivirals for pandemic influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Respiratory problems 2 years after acute bronchiolitis in infancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Efficacy of sequential annual vaccination with inactivated influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Respiratory syncytial virus puzzle: clinical features, pathophysiology, treatment, and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

T-cell recognition of influenza viral antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Intracellular neutralization of virus by immunoglobulin A antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Variation in severity of respiratory syncytial virus infections with subtype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Respiratory syncytial virus infections in infants and children: diagnosis and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Prospects for pandemic influenza control with currently available vaccines and antivirals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Respiratory syncytial virus infection causing neurological disorder in neonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Association of serum anti-neuraminidase antibody with resistance to influenza in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Safe administration of influenza vaccine in asthmatic children hypersensitive to egg proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Immune response of human volunteers and animals to vaccination with egg-grown influenza A (H1N1) virus is influenced by three amino acid substitutions in the haemagglutinin molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Influenza vaccines. A reappraisal of their use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Development of novel influenza virus vaccines and vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Does influenza vaccination exacerbate asthma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Determinants of immunity to influenza infection in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

DNA immunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Respiratory syncytial virus-immunoglobulin intravenous (RSV-IGIV) for respiratory syncytial viral infections: part I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Nebulized albuterol in acute bronchiolitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Toxic shock syndrome complicating influenza A in a child: case report and review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Secretory antibody following oral influenza immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Severity of respiratory syncytial virus infection is related to virus strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Immunization of cotton rats with the human respiratory syncytial virus F glycoprotein produced using a baculovirus vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Detection, pathogenesis, and therapy of respiratory syncytial virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Influenza infection in humans and pigs in southeastern China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

7 January 2021

Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

7 January 2021

Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

7 January 2021

Influenza: status and prospects for its prevention, therapy, and control

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

7 January 2021

Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970211-X

7 January 2021

10.1016/S0031-3955(05)70211-X

Identifiers

DOI

1 reference

29 July 2017

1 reference